vcrs removal from asx 300 and the asx sp ind, page-7

I see Ventrasist will play a pivotal roll in making LVAD devices a solution of choice for heart patients, even eventually replacing heart transplant since there is no problem of rejection.

Ventrasist is the 1st device with no mechanical contact and hence highly reliable. The risk is that some one may come up with a better design. HTW's is not it though. It's design is more complex and being smaller, it must work harder to move the same amount of blood -> higher risk of failure.